| PEC0394 | Viral suppression and contraceptive use among women initiating dolutegravir-containing antiretroviral therapy in Kenya: The Chaguo Langu study | E-poster | C7 |
| PEB0278 | Viral suppression by delivery and birth outcomes among pregnant women living with HIV using dolutegravir in the United States: A comparative effectiveness and safety analysis | Poster Exhibition | B44 |
| PEE1628 | Viral suppression in 'stable HIV+ patients in two community models of ART delivery: A cluster-randomized trial nested within the HPTN 071 (PopART) trial in Lusaka, Zambia | E-poster | E42 |
| PEB0112 | Virologic outcomes among patients on first-line antiretroviral therapy (ART) following transition to dolutegravir in a tertiary HIV clinic in Uganda | E-poster | B5 |
| OAA0106 | Virological and immunological evaluation of individuals with spontaneous persistent viral control without ART | Oral abstract session with live Q&A | A4 |
| PEB0296 | Virological characterization in newly HIV diagnosed adolescents in Spain during 1980-2017 | E-poster | B51 |
| PEB0241 | Virological efficacy and tolerability of dual therapy maintenance with dolutegravir plus lamivudine in heavily treatment experienced HIV-infected patients: Four years data from DOLULAM study | E-poster | B32 |
| PEB0337 | Virological outcome among vertically HIV infected patients transferred from pediatric care to adult units in Madrid | E-poster | B61 |
| PEE1504 | Virtual Intervention for HIV prevention among MSM - an online to Offline HIV Service Delivery model for MSM in Delhi, India | E-poster | E31 |
| LBPEA03 | Vpu inhibitor BIT225 alters T cell activation and homing plasma membrane receptor expression on CD4+T cells (CD28 and CCR7) and monocyte-derived macrophages (CD80 and CD86) | E-poster | A22 |